Borroto DG, Caballero GM, Chong LA

Language: Spanish
References: 34
Page: 97-113
PDF size: 207.16 Kb.

ABSTRACT

Introduction: biopsy of renal transplantation is the most effective method for diagnosing complications of graft dysfunction. Ratings established in Banff consensus meetings are invaluable tool to clarify, unify, and compare results.
Objective: evaluate the results of renal transplant biopsies, according to 2011 Banff classification, and compare them to the graft lifetime.
Methods: a retrospective, descriptive study was conducted on biopsies of kidney transplants performed at "Hermanos Ameijeiras" hospital which met usefulness criteria from 2007 to 2013. 89 biopsy specimens were assessed. The results were re-assessed by a renal pathology specialist, according to 2011 Banff classification, and correlated to the graft lifetime, according to the intervals: less than 3 months, 3 month to one year, and over one year.
Results: category 6 predominated: 35 (39.2%) other changes not due to rejections; Category 4: 30 (33.7%) rejection mediated by T cells and category 2: 10 (11.23%) rejection measured by antibodies. These three categories are detailed in their respective sub-classifications. In the first three months, the largest number of biopsies (69) were performed in which acute nephrotoxicity by cyclosporine A and rejection reactions by T cells and antibodies predominated; from three months to one year only 9 biopsies were performed mostly with same causes. After the year, the most frequently accounted for chronic damage in the 17 revised histological studies.
Discussion: graft biopsy is essential to diagnose Kidney transplant dysfunctions and set the correct therapeutic to complications that compromise the viability of the implant. 2011 Banff classification is an effective tool, according to established categories, to identify the entities aiming to transplant dysfunction and compare results obtained by different groups of researchers.
Conclusion: based on the application of 2011 Bannf classification, there is correlation of our results with those found in other reviewed study reports.

REFERENCES

1. El-Zoghby ZM. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527-35.

2. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation. 2001;71(11 Suppl):SS5-9.

3. Winfred WW, Taheri D, Tolkoff-Rubin N, Colvin RB. Clinical role of the renal transplant biopsy. Nat Rev Nephrol. 2012;8:110-21.

4. Wu C, Evans I, Joseph R. Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol. 2005;16:3437-44.

5. Nickeleit V. Pathology: donor biopsy evaluation at time of renal grafting. Nat Rev Nephrol. 2009;5:249-251.

6. Cosio FG, Grande JP, Wadei H. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant. 2005;5:2464-72.

7. Racusen LC, Regele H. The pathology of chronic allograft dysfunction. Kidney Int. 2010;78(Suppl 119):S27-S32.

8. Vázquez Martul E. Patología crónica del injerto renal. Nefrologia. 2008;28(4):373-80.

9. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, et al. Internacional standarization of criteria for histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411-22.

10. Mengel M, Sis B, Halloran PF. SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology. Am J Transplant. 2007;7:2221-6.

11. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 Meeting Report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10:464-71.

12. Mengel M. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012;12(3):563-70.

13. Vázquez EM, Veiga BJ. Patología del trasplante renal. Importancia de la biopsia en la correlación clínico patológica. Rev Esp Patol. 2002;35(3):279-94.

14. Solez K. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-60.

15. Qin Y, Fan Y, Mu X, Zhang F, Shen B, Liu Y, et al. Long-term use of ciclosporin on kidney transplant recipients surviving more than 10 years. Transplantation. 2014;69(7):558-60.

16. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37(6):602-12.

17. Borroto G, Guerrero C. Inmunosupresión de inducción en el trasplante renal en el Hospital "Hermanos Ameijeiras" de 1984 a 2012. Rev Cubana Med. 2013 [citado 20 Nov 2015];52(2):88-98. Disponible en: http://scielo.sld.cu/pdf/med/v52n2/med02213.pdf

18. Borroto G, Barceló M, Guerrero C, Rodríguez H. Frecuencia y factores de riesgo de la necrosis tubular aguda en el postrasplante renal inmediato. Rev Cubana Med. 2002;41(6):28-36.

19. Ounissi M, Cherif M, Abdallah TB, Bacha M, Hedri H, Abderrahim E, et al. Risk factors and consequences of delayed graft function. Saudi J Kidney Dis Transpl. 2013;24(2):243-6.

20. Ounissi M, Gargah T, Barbouch S, Boubaker K, Cherif M, Bacha MM. Acute tubular necrosis in kidney transplantation. Tunis Med. 2012;90(6):463-7.

21. Borroto G. Inmunosupresión de inducción en el trasplante renal. Rev Cubana Med. 2013 [citado 20 Nov 2015];52(1):1-3. Disponible en: http://scielo.sld.cu/pdf/med/v52n1/med01113.pdf

22. Wu K, Budde K, Lu H, Schmidt D, Liefeldt L, Glander P, et al. The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Trasplantation. 2014;97(11):1146-54.

23. Pape L, Becker JU, Immenschuh S, Ahlenstiel T. Acute and chronic antibodymediated rejection in pediatric kidney transplantation. Pediatr Nephrol. 2014;23(2):324-34.

24. Aktaş A. Transplanted kidney function evaluation. Semin Nusi Med. 2014;44(2):129-45.

25. Jung CW, Park KT, Kim SY, Kim SJ, Kim MG, Jo SK, et al. Clinical outcomes in kidney transplantation patients from deceased donors with acute kidney injury. Transplant Proc. 2013;45(8):2941-5.

26. Masin-Spasovska J, Spasovski G. Biopsy of the transplanted kidney - role of protocol biopsies. Prilozi. 2012;33(1):79-92.

27. Porta B, Pérez JJ, Jiménez NV, Crespo J. Estrategias para la individualización posológica de ciclosporina en pacientes con trasplante renal. Nefrología. 2004;25(5):395-410.

28. Moroni G, Longhi S, Quaglini S, Rognoni C, Simonini P, Binda V, et al. The impact of recurrence of primary glomerulonephritis on renal allograft outcome. Clin Transplant. 2014;28(3):368-76.

29. Lee SE, Min SI, Kim YS, Ha J, Ha IS, Cheong HI, et al. Recurrence of idiopathic focal segmental glomerulosclerosis after kidney transplantation: experience of a Korean tertiary center. Pediatr Transplant. 2014;18(4):369-76.

30. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol. 2001;12:828-33.

31. Stratta RJ, Oh CS, Sollinger HD, Pirsch JDE, Kalayoglu M, Belzer FO. Kidney retransplantation in the cyclosporine era. Transplantation. 1988;45:40-5.

32. Fadili W, Habib Allah M, Laouad I. Chronic renal allograft dysfunction: risk factors, immunology and prevention. Arab J Nephrol Transplant. 2013;6(1):45-50.

33. Vázquez Martul EJ. Veiga Barreiro. Patología del trasplante renal Importancia de la biopsia en la correlación clinico-patológica. Rev Esp Patol. 2002;35(3):279-94.

34. Rodrigues CA, Franco MF, Cristelli MP, Pestana JO, Tedesco-Silva H Jr. Clinicopathological characteristics and effect of late acute rejection on renal transplant outcomes. Transplantation. 2014;42(4):256-65.